Multiple System Atrophy

G. K. Wenning; K. Seppi; C. Scherfler; N. Stefanova; Z. Puschban

doi:10.1055/s-2001-13117

Seminars in Neurology, Table of Contents

Semin Neurol 2001; 21(1): 033-040
DOI: 10.1055/s-2001-13117

Multiple System Atrophy

G. K. Wenning, K. Seppi, C. Scherfler, N. Stefanova, Z. Puschban

Universitätsklinik für Neurologie, Innsbruck, Austria

Abstract

ABSTRACT

Multiple system atrophy (MSA) is an adult-onset sporadic progressive neurodegenerative disorder of unknown etiology. It is clinically characterized by the variable combination of autonomic failure, parkinsonism, cerebellar ataxia, and pyramidal signs. The present review summarizes up-to-date knowledge on the clinical diagnosis and molecular pathology of MSA. We also review the role of additional investigations that may support a clinical diagnosis of MSA. Finally, we briefly discuss the management of MSA, focusing on possible future therapeutic strategies.

KEYWORD

Multiple system atrophy - differential diagnosis - therapy

Full Text

References

REFERENCES

1 Bower J H, Maraganore D M, McDonnell S K, Rocca W A. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology . 1997; 49 1284-1288
2 Schrag A, Ben-Shlomo Y, Quinn N P. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet . 1999; 354 1771-1775
3 Gilman S, Low P A, Quinn N. Consensus statement on the diagnosis of multiple system atrophy. J Auton Nerv Syst . 1998; 74 189-192
4 Wenning G K, Ben Shlomo Y, Magalhaes M, Daniel S E, Quinn N P. Clinical features and natural history of multiple system atrophy: an analysis of 100 cases. Brain . 1994; 117 835-845
5 Wenning G K, Tison F, Ben Shlomo Y, Daniel S E, Quinn N P. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord . 1997; 12 133-147
6 Quinn N. Multiple system atrophy: the nature of the beast. J Neurol Neurosurg Psychiatry . 1989; 78-89 (78-89)
7 Quinn N. Multiple system atrophy. In: Marsden CD, Fahn S, eds. Movement Disorders 3 London: Butterworth-Heinemann 1994: 262-281
8 Litvan I, Booth V, Wenning G K. Retrospective application of a set of clinical diagnostic criteria for the diagnosis of multiple system atrophy. J Neural Transm . 1998; 105 217-227
9 Poewe W H, Wenning G K. The natural history of Parkinson's disease. Ann Neurol . 1998; S1-S9 (S1-S9)
10 Wenning G K, Scherfler C, Granata R. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J Neurol Neurosurg Psychiatry . 1999; 67 620-623
11 Litvan I, Mangone C A, McKee A. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry . 1996; 60 615-620
12 Kompoliti K, Goetz C G, Boeve B F. Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol . 1998; 55 957-961
13 Wenning G K, Litvan I, Jankovic J. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry . 1998; 64 184-189
14 Gilman S, Koeppe R A, Junck L. Benzodiazepine receptor binding in the cerebellum in multiple system atrophy and olivopontocerebellar atrophy studied with positron emission tomography. Adv Neurol . 1996; 69 459-466
15 Mathias C, Bannister R. Investigation of autonomic disorders. In: Bannister R, Mathias C, eds. Autonomic Failure London: Oxford University Press 1992: 255-290
16 Wenning G K, Litvan I, Verny M. Is EEG useful in the differential diagnosis of parkinsonism?. Parkinsonism Relat Disord . 1998; 4 79-80
17 Beck R O, Betts C D, Fowler C J. Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. J Urol . 1994; 151 1336-1341
18 Schwarz J, Weis S, Kraft E. Signal changes on MRI and increases in reactive microgliosis, astrogliosis, and iron in the putamen of two patients with multiple system atrophy. J Neurol Neurosurg Psychiatry . 1996; 60 98-101
19 Schrag A, Kingsley D, Phatouros C. Clinical usefulness of magnetic resonance imaging in multiple system atrophy. J Neurol Neurosurg Psychiatry . 1998; 65 65-71
20 Schulz J B, Skalej M, Wedekind D. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol . 1999; 45 65-74
21 Davie C A, Wenning G K, Barker G J. Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Ann Neurol . 1995; 37 204-210
22 Schwarz J, Tatsch K, Gasser T. 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism. Mov Disord . 1998; 13 16-19
23 Brucke T, Asenbaum S, Pirker W. Measurement of the dopaminergic degeneration in Parkinson's disease with [¹²³I] beta-CIT and SPECT: correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl . 1997; 50 9-24
24 Terao S, Sobue G, Hashizume Y, Mitsuma T, Takahashi A. Disease-specific patterns of neuronal loss in the spinal ventral horn in amyotrophic lateral sclerosis, multiple system atrophy and X-linked recessive bulbospinal neuronopathy, with special reference to the loss of small neurons in the intermediate zone. J Neurol . 1994; 241 196-203
25 Daniel S E. The neuropathology and neurochemistry of multiple system atrophy. In: Bannister R, Mathias C, eds. A Textbook of Clinical Disorders of Autonomic Nervous System 3rd ed. Oxford: Oxford University Press 1992: 564-585
26 Wenning G K, Ebersbach G, Verny M. Progression of falls in postmortem-confirmed parkinsonian disorders. Mov Disord . 1999; 14 947-950
27 Papp M I, Lantos P L. Accumulation of tubular structures in oligodendroglial and neuronal cells as the basic alteration in multiple system atrophy. J Neurol Sci . 1992; 107 172-182
28 Lantos P L. The definition of multiple system atrophy: a review of recent developments. J Neuropathol Exp Neurol . 1998; 57 1099-1111
29 Papp M I, Lantos P L. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain . 1994; 117 235-243
30 Papp M I, Kahn J E, Lantos PL.Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci . 1989; 94 79-100
31 Cairns N J, Atkinson P F, Hanger D P, Anderton B H, Daniel S E, Lantos P L. Tau protein in the glial cytoplasmic inclusions of multiple system atrophy can be distinguished from abnormal tau in Alzheimer's disease. Neurosci Lett . 1997; 230 49-52
32 Spillantini M G, Crowther R A, Jakes R, Cairns N J, Lantos P L, Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett . 1998; 251 205-208
33 Takeda A, Arai N, Komori T, Iseki E, Kato S, Oda M. Tau immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett . 1997; 234 63-66
34 Goedert M, Spillantini M G. Lewy body diseases and multiple system atrophy as alpha-synucleinopathies. Mol Psychiatry . 1998; 3 462-465
35 Spillantini M G, Schmidt M L, Lee V M, Trojanowski J Q, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature . 1997; 388 839-840
36 Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H. α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett . 1998; 249 180-182
37 Arima K, Ueda K, Sunohara N. NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. Acta Neuropathol (Berl) . 1998; 96 439-444
38 Tu P, Galvin J E, Baba M. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α-synuclein. Ann Neurol . 1998; 44 415-422
39 Clayton D F, George J M. Synucleins in synaptic plasticity and neurodegenerative disorders. J Neurosci Res . 1999; 58 120-129
40 Dickson D W, Liu W, Hardy J. Widespread alterations of alpha-synuclein in multiple system atrophy. Am J Pathol . 1999; 155 1241-1251
41 Abeliovich A, Schmitz, Farinas I. Mice lacking α-synclein display functional deficits in the nigrostriatal dopamine system. Neuron . 2000; 25 239-252
42 Farrer M, Wavrant-De Vrieze F. Low frequency of alpha-synuclein mutations in familial Parkinson's disease. Ann Neurol . 1998; 43 394-397
43 Kruger R, Kuhn W, Muller T. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet . 1998; 18 106-108
44 Ozawa T, Takano H, Onodera O. No mutation in the entire coding region of the alpha-synuclein gene in pathologically confirmed cases of multiple system atrophy. Neurosci Lett . 1999; 270 110-112
45 Colosimo C, Merello M, Pontieri F E. Amantadine in parkinsonian patients unresponsive to levodopa: a pilot study [letter]. J Neurol . 1996; 243 422-425
46 Lang A E, Lozano A M. Parkinson's disease: second of two parts. N Engl J Med . 1998; 339 1130-1143
47 Wenning G K, Granata R, Laboyrie P M, Quinn N P, Jenner P, Marsden C D. Reversal of behavioural abnormalities by fetal allografts in a novel rat model of striatonigral degeneration. Mov Disord . 1996; 11 522-532
48 Puschban Z, Scherfler C, Granata R. Autoradiographic study of striatal dopamine reuptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or co-grafts. Neuroscience . 2000; 95 377-388
49 Wenning G K, Tison F, Scherfler C. Towards neurotransplantation in multiple system atrophy: clinical rationale, pathophysiological basis, and preliminary experimental evidence. Cell Transplant . 2000; 9 279-288
50 Wenning G K, Ben-Shlomo Y, Magalhaes M, Daniel S E, Quinn N P. Clinicopathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatry . 1995; 58 160-166
51 Wenning G K, Ben-Shlomo Y, Hughes A, Daniel S E, Lees A, Quinn N P. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease?. J Neurol Neurosurg Psychiatry . 2000; 68 434-440
52 Litvan I, Campbell G, Mangone C A. Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders?. <~>A clinicopathological study. Brain . 1997; 120 65-74
53 Schulz J B, Klockgether T, Petersen D. Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT. J Neurol Neurosurg Psychiatry . 1994; 57 1047-1056
54 Herrlinger K, Waldner R, Ceballos-Baumann A, Weindl A. 123-I-iodobenzamide-SPECT dopamine D2 receptor imaging in normals, patients with Parkinson's disease and other akinetic-rigid syndromes. Mov Disord . 1992; 7 146
55 van Royen E, Verhoeff N F, Speelman J D, Wolters E C, Kuiper M A, Janssen A G. Multiple system atrophy and progressive supranuclear palsy: diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography. Arch Neurol . 1993; 50 513-516
56 Pirker W, Asenbaum S, Wenger S. Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease. J Nucl Med . 1997; 38 1711-1717
57 De Volder G A, Francart J, Laterre C. Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration. Ann Neurol . 1989; 26 239-247
58 Eidelberg D, Takikawa S, Moeller J R. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease. Ann Neurol . 1993; 33 518-527
59 Otsuka M, Kuwabara Y, Ichiya Y. Differentiating between multiple system atrophy and Parkinson's disease by positron emission tomography with ¹⁸F-dopa and ¹⁸F-FDG. Ann Nucl Med . 1997; 11 251-257
60 Gilman S, Koeppe R A, Junck L, Kluin K J, Lohman M, St. Laurent T R. Benzodiazepine receptor binding in the cerebellum in multiple system atrophy and olivopontocerebellar atrophy studied with positron emission tomography. Adv Neurol . 1996; 69 459-466
61 Antonini A, Leenders K L, Vontobel P. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain . 1997; 120 2187-2195
62 Brooks D J, Ibanez V, Sawle G V. Differing patterns of striatal ¹⁸F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol . 1990; 28 547-555
63 Eidelberg D. Positron emission tomography studies in parkinsonism. Neurol Clin . 1992; 10 421-433
64 Gilman S, Koeppe R A, Junck L. Decreased striatal monoaminergic terminals in multiple system atrophy detected with positron emission tomography. Ann Neurol . 1999; 45 769-777
65 Shinotoh H, Inoue O, Hirayama K. Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study. J Neurol Neurosurg Psychiatry . 1993; 56 467-472
66 Brooks D J, Ibanez V, Sawle G V. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with ¹¹C-raclopride and positron emission tomography. Ann Neurol . 1992; 31 184-192
67 Momose T, Sasaki Y. Striatal dopamine D2 receptor in Parkinson disease and its related disorders assessed by C-11 NMSP and PET. Nippon Rinsho . 1997; 55 227-232
68 Burn D J, Rinne J O, Quinn N P, Lees A J, Marsden C D, Brooks D J. Striatal opioid receptor binding in Parkinson's disease, striatonigral degeneration and Steele-Richardson-Olszewski syndrome, a [¹¹C]diprenorphine PET study. Brain . 1995; 118 951-958
69 Schrag A, Rinne J O, Burn D J. Olivopontocerebellar atrophy and multiple system atrophy: clinical follow-up of 10 patients studied with PET [letter; comment]. Ann Neurol . 1998; 44 151-152